CT-P13

March 2, 2020March 2, 2020

Remsima in New Injection Form Shows Safety and Efficacy in Trial

News

A new formulation of CT-P13, a biosimilar of Remicade (infliximab), given as an under-the-skin injection is as safe and effective for people with active Crohn’s disease (CD) and ulcerative colitis (UC) as ... Read more

December 12, 2019December 17, 2019

Injection Form of Remicade Biosimilar for IBD Similar to Approved Infusion, Phase 1 Trial Shows

News

A new formulation of CT-P13, a biosimilar of Remicade (infliximab), that is given as an under-the-skin (subcutaneous) injection, was shown to be as safe and effective in treating inflammatory bowel disease ... Read more

July 22, 2019July 22, 2019

Remicade Biosimilar CT-P13 Found Safe, Effective for IBD Treatment in Italian Study

News

CT-P13, a biosimilar of Remicade (infliximab), is safe and effective for the treatment of inflammatory bowel disease (IBD), a study suggests. The study, “Infliximab biosimilar CT-P13 is effective and safe ... Read more

November 1, 2017

Effectiveness, Safety of Remicade’s Biosimilar, Inflectra, Confirmed in Phase 3 Trial

News

Switching Crohn’s disease patients from Remicade (infliximab) to its biosimilar Inflectra has no negative impact to treatment safety or effectiveness, a Phase 3 clinical trial shows. Pfizer and Celltrion Healthcare jointly presented those ... Read more

May 22, 2017May 22, 2017

Switch From Remicade to Celltrion’s Biosimilar CT-P13 Safe in IBD, Clinical Trial Concludes

News

Patients with inflammatory bowel disease (IBD) may safely switch from Remicade (infliximab) to its biosimilar version CT-P13 — sold as Remsima and Inflectra — according to recently published clinical trial ... Read more

February 12, 2016February 12, 2016

First Biosimilar Therapy for Crohn’s Disease and Ulcerative Colitis Is Focus of FDA Meeting

Crohn's Disease, IBD News, News, Ulcerative colitis

The U.S. Food and Drug Administration (FDA) Arthritis Advisory Committee recently met to review a biologics license application (BLA) submitted by Celltrion Inc. for its compound CT-P13, a proposed biosimilar to Remicade ... Read more